Abstract
Mitochondrial dysfunction has been widely implicated in the etiology of Alzheimers disease (AD). Evidence shows a mitochondrial-mediated impairment of autophagy that potentiates amyloid-β (Aβ) deposition. Accordingly, recent data obtained from AD models, in which mitochondrial alterations are a prominent feature, demonstrated abnormalities in microtubule network, involving tubulin and tau post-translational modifications. In this review we will discuss mitochondrial- regulated processes where mitochondrial malfunction is likely to start a sequence of events leading to sirtuin- 2 activation, microtubule network breakdown, and impairment of the autophagic pathway. Because sirtuin-2 activity depends on cellular NAD+ availability, mitochondrial regulation of NAD+ levels may contribute to an increase in sirtuinmediated tubulin deacetylation. A vicious cycle become installed which potentiates tau hyperphosphorylation, together with Aβ overproduction and deposition. Overall, targeting microtubule network constitutes a promising strategy for pharmacological therapy in AD.
Keywords: Alzheimer's disease, amyloid-β, autophagy, microtubule network, mitochondria, tau, calcium homeostasis, oxidative phosphorylation, AD development, oxidative stress markers, neurodegeneration, mitochondrial integrity, resonance spectroscopy
Current Alzheimer Research
Title: Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Volume: 8 Issue: 5
Author(s): D. F.F. Silva, A. R. Esteves, C. R. Oliveira and S. M. Cardoso
Affiliation:
Keywords: Alzheimer's disease, amyloid-β, autophagy, microtubule network, mitochondria, tau, calcium homeostasis, oxidative phosphorylation, AD development, oxidative stress markers, neurodegeneration, mitochondrial integrity, resonance spectroscopy
Abstract: Mitochondrial dysfunction has been widely implicated in the etiology of Alzheimers disease (AD). Evidence shows a mitochondrial-mediated impairment of autophagy that potentiates amyloid-β (Aβ) deposition. Accordingly, recent data obtained from AD models, in which mitochondrial alterations are a prominent feature, demonstrated abnormalities in microtubule network, involving tubulin and tau post-translational modifications. In this review we will discuss mitochondrial- regulated processes where mitochondrial malfunction is likely to start a sequence of events leading to sirtuin- 2 activation, microtubule network breakdown, and impairment of the autophagic pathway. Because sirtuin-2 activity depends on cellular NAD+ availability, mitochondrial regulation of NAD+ levels may contribute to an increase in sirtuinmediated tubulin deacetylation. A vicious cycle become installed which potentiates tau hyperphosphorylation, together with Aβ overproduction and deposition. Overall, targeting microtubule network constitutes a promising strategy for pharmacological therapy in AD.
Export Options
About this article
Cite this article as:
F.F. Silva D., R. Esteves A., R. Oliveira C. and M. Cardoso S., Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease, Current Alzheimer Research 2011; 8 (5) . https://dx.doi.org/10.2174/156720511796391872
DOI https://dx.doi.org/10.2174/156720511796391872 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Can Apolipoproteins and Complement Factors be Biomarkers of Alzheimer’s Disease?
Current Alzheimer Research Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry Current Challenges and Updates on the Therapy of Fungal Infections
Current Topics in Medicinal Chemistry Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design CT and CT-guided Percutaneous Needle Biopsy in Diagnosis of Primary Pulmonary Cryptococcosis in Immunocompetent Patients
Current Medical Imaging Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Methoxychalcones: Effect of Methoxyl Group on the Antifungal, Antibacterial and Antiproliferative Activities
Medicinal Chemistry Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease
Current Alzheimer Research Antimicrobial and Antifungal Properties of Leaves to Root Extracts and Saponin Fractions of <i>Chlorophytum borivilianum</i>
Current Bioactive Compounds Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Patent Selections:
Recent Patents on Regenerative Medicine